Fig. 3: Experimental design of the protection study.
Twelve female cynomolgus macaques were treated with Depo-Provera. Four weeks (wk) later, 2 mL of either (A) a placebo HEC gel (no Ab, n = 6, control group) or (B) 10-1074 Ab (n = 6, treated group) formulated in HEC gel at the concentration of 5 mg/g (10 mg of Ab/treatment/animal) were applied in the vaginal vault. One hour later, all animals were exposed to 107 SHIV162P3-infected splenocytes. The treatment was repeated weakly for up to 8 challenges or until animals were confirmed viremic on two consecutive weeks. Blood was collected at baseline (before the first challenge), weekly up to week 12 after the first challenge, then at weeks 15, 19, 23, 31, 39, 43, 52, and 58. 15 weeks after the first challenge, inguinal lymph node biopsies were collected. The dagger indicates the time of the necropsy.
